Chlorthalidone
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | HYGROTON | — | 1960-04-07 | fda.gov ↗ |
Trials 57 · a red edge is where a trial was stopped
Also used as a comparator or background therapy in 24 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT06287580 Comparator | Aug 2024 → Feb 2026 | essential hypertension | University of Texas Southwestern Medical Center | Completed | No outcome recorded |
| Phase 13 trials | ||||||
| Phase 1 | NCT05090449 Comparator | May 2019 → Apr 2020 | — | Laboratorios Silanes S.A. de C.V. | Completed | No outcome recorded |
| Phase 1 | NCT02496910 Comparator | Jun → Sep 2015 | hypertensive disorder | Yuhan Corporation | Completed | No outcome recorded |
| Phase 1 | NCT01806363 Comparator | Nov 2012 → Jun 2013 | hypertensive disorder | HanAll BioPharma Co., Ltd. | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT07238400 Comparator | Mar 2026 → Mar 2029 expected | hypertensive disorder | Massachusetts General Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06111885 Comparator | Oct 2024 → Jun 2027 expected | urolithiasis | Insel Gruppe AG, University Hospital Bern | Recruiting | No outcome recorded |
| Phase 2 | NCT02236520 Comparator | Sep 2014 → May 2018 | hypertensive disorder | Vanderbilt University | Completed | No outcome recorded |
| Phase 37 trials | ||||||
| Phase 3 | NCT02185417 Comparator | Jun 2016 → Oct 2022 | hypertensive disorder | VA Office of Research and Development | Completed | No outcome recorded |
| Phase 3 | NCT00971165 Comparator | Jul 2010 → Sep 2014 | hypertensive disorder | Hospital de Clinicas de Porto Alegre | Completed | No outcome recorded |
| Phase 3 | NCT00591773 Comparator | Sep 2007 → Mar 2009 | essential hypertension | Takeda | Completed | No outcome recorded |
| Phase 3 | NCT00695955 Background | Jun 2007 → May 2010 | essential hypertension | Takeda | Completed | No outcome recorded |
| Phase 3 | NCT00696384 Background | Jun 2007 → Apr 2009 | essential hypertension | Takeda | Completed | No outcome recorded |
| Phase 3 | NCT00241839 Comparator | Aug 2005 → May 2011 | heart disorder, hypertensive disorder | University of Florida | Completed | No outcome recorded |
| Phase 3 | NCT00000620 Background | Sep 1999 → Jun 2009 | atherosclerosis, coronary artery disorder, hyperlipoproteinemia, hypertensive disorder +1 | National Heart, Lung, and Blood Institute (NHLBI) | Completed | No outcome recorded |
| Phase 46 trials | ||||||
| Phase 4 | NCT05593055 Comparator | Aug 2023 → Apr 2027 expected | hypertensive disorder | Brigham and Women's Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT05275907 Comparator | Jul 2022 → Oct 2023 | hypertensive disorder, impaired renal function disease | Northwestern University | Withdrawn | No outcome recorded |
| Phase 4 | NCT04519164 Comparator | Dec 2020 → Sep 2025 | hypertensive disorder, metabolic syndrome X | Brigham and Women's Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01748123 Comparator | Aug 2016 → Jun 2017 | hypertensive disorder | Johns Hopkins University | Withdrawn | No outcome recorded |
| Phase 4 | NCT01368536 Comparator | May 2011 → Feb 2012 | hypertensive disorder, type 2 diabetes mellitus | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 4 | NCT00353652 Comparator | Jan 2005 → Jan 2013 | hypertensive disorder | University of Texas Southwestern Medical Center | Completed | No outcome recorded |
| Phase not applicable4 trials | ||||||
| — | NCT02665117 Comparator | Jan 2015 → Nov 2022 | hypertensive disorder | University of Texas Southwestern Medical Center | Completed | No outcome recorded |
| — | NCT03560804 Comparator | Nov 2014 → Sep 2017 | arteriosclerosis disorder | AHEPA University Hospital | Completed | No outcome recorded |
| — | NCT02121041 Comparator | May 2014 → Sep 2015 | hypertensive disorder | Anthony J Viera, MD, MPH | Completed | No outcome recorded |
| — | NCT00684489 Comparator | Sep 2003 → Mar 2005 | essential hypertension | Medical University of South Carolina | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 84 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Chlorthalidone | “The participant's blood pressure medication regimen will then be altered to initiate a thiazide-type (hydrochlorothiazide or chlorthalidone) or loop diuretic (furosemide,...” NCT04192110 ↗80“Single oral dose C52R1M(FDC, Valsartan/Amlodipine) 160/5 mg tablet and C52R2(Chlorthalidone) 25 mg tablet taken together” NCT05077462 ↗ “Fixed-dose combination tablet containing valsartan 160 mg, amlodipine 10 mg, and chlorthalidone 25 mg.” NCT07116863 ↗ “Hydrochlorothiazide, metolazone, chlorthalidone, chlorothiazide, bendroflumethiazide, indapamide” NCT04330300 ↗ “renin guided therapeutics-chlorothiazide, chlorthalidone, hydrochlorothiazide” NCT00684489 ↗ “Chlorthalidone plus amiloride 25 and 5 mg daily, taking in the morning” NCT01896661 ↗ “telmisartan/amlodipine/chlorthalidone 20/2.5/6.25 mg” PMID 41717679 ↗ Feb 2026 “telmisartan/amlodipine/chlorthalidone 40/5/12.5 mg” NCT02620163 ↗ “amlodipine, Losartan, Chlorthalidone FDC” NCT02916602 ↗ “C52R2(Chlorthalidone) 25 mg tablet” NCT05077475 ↗ “chlorthalidone (Thalitone)” NCT00000620 ↗ |
| Known as | chlorthalidone (Thalitone) | “chlorthalidone (Thalitone)” NCT00000620 ↗ |
| Known as | CTD | “We performed 12-hour urine collections in 7 patients taking 25 mg of chlorthalidone (CTD) and 10 patients taking 25 mg of hydrochlorothiazide (HCTZ).” PMID 40194294 ↗ Apr 20254“chlorthalidone (CTD) is a thiazide-like diuretic used for treating hypertension and decreases serum K.” NCT05222191 ↗ “Chlorthalidone (CTD) is a thiazide-like diuretic and an effective antihypertensive drug” PMID 32663820 ↗ Jul 2020 “Chlorthalidone (CTD) may be superior to hydrochlorothiazide (HCTZ)” PMID 36067089 ↗ Sep 2022 “Chlorthalidone (CTD)” NCT02185417 ↗ |
| Known as | HIGROTON 50 | “Chlorthalidone (HIGROTON® 50)” NCT05090449 ↗ |
| Known as | Hygroton (brand name for chlorthalidone) | “Hygroton (brand name for chlorthalidone)” NCT05411991 ↗ |
| Modality | Other / unclassified | “Chlorthalidone is a thiazide-like diuretic” NCT00591773 ↗ |
| Route | Oral | “chlorthalidone 25 mg, tablets, orally, once daily” NCT00591773 ↗ |